Matches in Nanopublications for { ?s ?p "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP859103.RAvavVO_Cg0iXLbPVLZbF3FXESFUUsmFEjNQ1dbY6bRKA130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP859103.RAvavVO_Cg0iXLbPVLZbF3FXESFUUsmFEjNQ1dbY6bRKA130_provenance.
- assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP348062.RAaNV1F7TdVFWh0fhgRYrP6CmewwkNN6j4eHx18SIf2as130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348062.RAaNV1F7TdVFWh0fhgRYrP6CmewwkNN6j4eHx18SIf2as130_provenance.
- NP570591.RAFi8IUSL43rAxKtImTwzlzMa6mki0u20biGcYnYfa_Jw130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570591.RAFi8IUSL43rAxKtImTwzlzMa6mki0u20biGcYnYfa_Jw130_provenance.
- NP324035.RAT0twd7x1Eh83JCuPm2sbL5FIzwaC8XAQVcVqEwnSaVg130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324035.RAT0twd7x1Eh83JCuPm2sbL5FIzwaC8XAQVcVqEwnSaVg130_provenance.
- NP324039.RAUtmKen2hG1VBMQW1KmOWxTCdbR9p0jlKS8JoOPsPc9U130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324039.RAUtmKen2hG1VBMQW1KmOWxTCdbR9p0jlKS8JoOPsPc9U130_provenance.
- NP324040.RAWCAy54vc1OM4zG7JRjkAPvSQu5j8W_Pwoisv2fP0poI130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324040.RAWCAy54vc1OM4zG7JRjkAPvSQu5j8W_Pwoisv2fP0poI130_provenance.
- NP348217.RA4o3jOLVmH6z1TNmYcC3hAzc9kBS414AAp58ckKKbOEc130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348217.RA4o3jOLVmH6z1TNmYcC3hAzc9kBS414AAp58ckKKbOEc130_provenance.
- NP324038.RA8DBIa9FD4rZj8bHJ-8pvzPURg2mpmmdp7OFnQXrsLNE130_assertion description "[Therefore, we evaluated the feasibility of intracavitary injection of E1A gene complexed with DC-Chol cationic liposome (DCC-E1A) in patients with both HER-2/neu-overexpressing and low HER-2/neu-expressing breast and ovarian cancers in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324038.RA8DBIa9FD4rZj8bHJ-8pvzPURg2mpmmdp7OFnQXrsLNE130_provenance.